share_log

Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers; Strategic Agreement Expands Vir Portfolio With Three Clinical Stage Assets In Areas Of High...

Benzinga ·  Sep 9 16:16

Vir Biotechnology Announces Closing Of Exclusive Worldwide License Agreement With Sanofi For Multiple Potential Best-In-Class Clinical-Stage T-Cell Engagers; Strategic Agreement Expands Vir Portfolio With Three Clinical Stage Assets In Areas Of High Unmet Need

– License of proprietary masking platform further strengthens Vir's drug discovery capabilities in oncology and infectious disease –

– Strategic agreement expands Vir portfolio with three clinical stage assets in areas of high unmet need –

Vir Biotechnology, Inc. (NASDAQ:VIR) today announced that the exclusive worldwide license agreement with Sanofi announced on August 1, 2024, has closed following expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The agreement provides Vir with an exclusive worldwide license to three clinical-stage masked T-cell engagers (TCEs) with potential applications in a range of cancers and exclusive use of the proprietary PRO-XTENTM masking platform for oncology and infectious disease. Key employees from Sanofi with extensive scientific and development expertise in TCEs, and in-depth experience using the PRO-XTEN platform, will join Vir. Further information about the TCEs and their respective development plans will be provided at Vir's upcoming R&D Day in November.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment